Brokerages Set Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) Target Price at $20.20

Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) has been assigned an average recommendation of “Moderate Buy” from the twelve ratings firms that are covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, four have given a hold recommendation and seven have issued a buy recommendation on the company. The average 12 month price target among brokerages that have updated their coverage on the stock in the last year is $20.20.

Several analysts have recently issued reports on the stock. Citigroup reiterated an “outperform” rating on shares of Bicycle Therapeutics in a research report on Friday, October 31st. Citizens Jmp lifted their price objective on Bicycle Therapeutics from $10.00 to $12.00 and gave the stock a “market outperform” rating in a report on Friday, October 31st. Royal Bank Of Canada reissued a “sector perform” rating and set a $11.00 target price (down previously from $27.00) on shares of Bicycle Therapeutics in a report on Friday, October 31st. JMP Securities set a $12.00 price target on Bicycle Therapeutics in a research note on Friday, October 31st. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Bicycle Therapeutics in a research report on Monday, December 22nd.

Insider Transactions at Bicycle Therapeutics

In related news, CFO Alethia Young sold 4,334 shares of the business’s stock in a transaction dated Monday, January 5th. The shares were sold at an average price of $6.49, for a total transaction of $28,127.66. Following the transaction, the chief financial officer directly owned 87,081 shares in the company, valued at approximately $565,155.69. The trade was a 4.74% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CEO Kevin Lee sold 10,989 shares of the stock in a transaction dated Monday, January 5th. The shares were sold at an average price of $6.46, for a total transaction of $70,988.94. Following the completion of the sale, the chief executive officer owned 618,996 shares of the company’s stock, valued at approximately $3,998,714.16. The trade was a 1.74% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 38,029 shares of company stock valued at $251,966 over the last quarter. Company insiders own 8.50% of the company’s stock.

Hedge Funds Weigh In On Bicycle Therapeutics

Institutional investors have recently added to or reduced their stakes in the stock. Assetmark Inc. grew its holdings in Bicycle Therapeutics by 74.9% in the 3rd quarter. Assetmark Inc. now owns 3,625 shares of the company’s stock valued at $28,000 after buying an additional 1,552 shares in the last quarter. Clearstead Advisors LLC boosted its position in shares of Bicycle Therapeutics by 234.2% during the 4th quarter. Clearstead Advisors LLC now owns 4,655 shares of the company’s stock valued at $33,000 after acquiring an additional 3,262 shares during the last quarter. Brooklyn Investment Group purchased a new stake in shares of Bicycle Therapeutics in the fourth quarter valued at about $69,000. Ausdal Financial Partners Inc. purchased a new stake in shares of Bicycle Therapeutics in the second quarter valued at about $70,000. Finally, Pinnacle Wealth Management Advisory Group LLC acquired a new stake in Bicycle Therapeutics during the fourth quarter worth about $71,000. Hedge funds and other institutional investors own 86.15% of the company’s stock.

Bicycle Therapeutics Price Performance

Shares of BCYC stock opened at $5.24 on Friday. Bicycle Therapeutics has a 1-year low of $5.18 and a 1-year high of $13.11. The company has a market cap of $363.50 million, a price-to-earnings ratio of -1.45 and a beta of 1.63. The stock has a 50 day simple moving average of $6.60 and a 200-day simple moving average of $7.10.

Bicycle Therapeutics Company Profile

Bicycle Therapeutics plc is a clinical-stage biotechnology company specializing in the discovery and development of novel peptide therapeutics based on its proprietary bicyclic peptide platform. The company’s core technology leverages constrained peptide structures that combine the binding specificity of biologics with the favorable tissue-penetration properties of small molecules. This approach is designed to generate highly selective drug candidates with potential applications across a range of therapeutic areas, including oncology, neuroscience and immunology.

Bicycle Therapeutics maintains a diversified pipeline of internally developed programs as well as collaborations with leading pharmaceutical partners.